Huntington's Disease Research

Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.

Huntington's Disease Research Products Targets

Products for Huntington's Disease Research - Page 44

Cat.No. Product Name Information/Activity
BCC7968 TRC 051384 TRC051384 is a heat shock protein 70 (HSP70) inducer.
BCC2121 17-AAG (KOS953) Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin (17-AAG) depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin (17-AAG) also downregulates the stk38 gene expression.
BCC2124 BIIB021 BIIB021 is an orally available, fully synthetic inhibitor of HSP90 with Ki and EC50 of 1.7 nM and 38 nM, respectively.
BCC1175 17-DMAG (Alvespimycin) HCl Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of Hsp90, binding to Hsp90 with EC50 of 62±29 nM.
BCC5600 EC 144 911397-80-3
BCC7676 Gedunin 2753-30-2
BCC2125 Geldanamycin Selective Hsp90 inhibitor; breast cancer stem cell inhibitor,Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
BCC7132 Herbimycin A Antiangiogenic. Inhibits Src family kinases and Hsp90
BCC7551 Macbecin I 73341-72-7
BCC1872 PU-H71 PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.